The molecular progression of endometrial cancer is poorly understood, and both genetic and epigenetic factors play a role. Survivin is a member of the inhibitor of apoptosis (IAP) gene family and contains a canonical CpG island that has been described as epigenetically regulated. As survivin is overexpressed in endometrial tumors, we hypothesized that hypomethylation could explain this expression pattern. Surprisingly, methylation-specific PCR and pyrosequencing showed that survivin was hypermethylated in endometrial tumors and correlated with increased survivin expression. We speculated that methylation could inhibit the binding of p53, a repressor of survivin expression. Our data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation. We are the first to report survivin de-repression by DNA methylation. We also present microarray data, which suggest that de-repression by methylation is a general mechanism of p53 regulation. Demethylation induced by decitabine is traditionally thought to be active in tumors by allowing the reexpression of tumor suppressor genes. However, our results indicate that an additional important mechanism is to decrease the expression of oncogenes.
Survivin (BIRC5) has received much attention since its discovery in 1997 because of its dual function in apoptosis and cell cycle regulation, and its unique expression pattern. Survivin is highly expressed during embryonic development, but is negligibly expressed in most highly differentiated adult tissues except liver, testis, brain, ovary and endometrium, in which the expression is detectable, but minimal, compared with its expression in tumors of those tissue types (Konno et al., 2000; Fukuda and Pelus, 2006) . Transcription of the survivin gene is driven through two critical Sp1 sites upstream of the start site. The survivin promoter also contains several cell cycle-dependent elements and cell cycle homology regions, and is GC-rich with a canonical CpG island extending into exon 1 (Ambrosini et al., 1997 (Ambrosini et al., , 1998 Li and Altieri, 1999) , which has been shown to be epigenetically regulated (Hattori et al., 2001; Esteve et al., 2005; Hopfer et al., 2007) .
In the United States, endometrial cancer is the most common malignancy of the female reproductive tract (Jemal et al., 2008) . The type 1 endometrioid adenocarcinomas (EC) represent 80% of endometrial cancer cases. Common genetic abnormalities in EC include mutations in PTEN, K-RAS, PI3CA and CTNNB1; TP53 mutations are very rare (Prat et al., 2007) . Epigenetic studies have linked hypermethylation to the loss of expression of DNA repair enzymes, MLH1 and O6-methylguanine DNA methyltransferase (MGMT), the tumor suppressors, PTEN, p53 and TIG1, the progesterone receptor, the b-catenin/Wnt signaling regulator, APC (adenomatous polyposis coli), the transcription factor, C/EBPa, and the differentiation gene, HoxA10 (Furlan et al., 2006; Shang, 2006; Yoshida et al., 2006; Zhou et al., 2007) . Alternatively, hypomethylation has been described as a contributing factor for oncogene overexpression in EC. The oncogene, PAX2, (Wu et al., 2005; Shang, 2006) and the metastasis promoting gene, S100A4, (Xie et al., 2007) were shown to be hypomethylated in aggressive endometrial cancer. As survivin levels progressively increased in EC tumors, we hypothesized that progressive DNA hypomethylation could explain this expression pattern.
Using quantitative reverse transcriptase PCR, we quantified survivin transcript levels from normal postmenopausal endometrial samples and EC samples. Survivin mRNA levels were significantly increased in grade 2 and grade 3 endometrial tumors compared with normal samples (Figure 1a ). This suggests that survivin overexpression is selective toward high-grade, poorly differentiated tumors. This finding is consistent with reverse transcriptase PCR and immunohistochemistry data from other laboratories (Lehner et al., 2002; Takai et al., 2002; Erkanli et al., 2006 Erkanli et al., , 2007 .
Surprisingly, analysis of the survivin promoter with methylation-specific PCR showed that normal endometrial samples were completely unmethylated, whereas methylation progressively increased from low-grade to high-grade endometrial tumors correlating with increased survivin expression (Figure 1b) . In an independent set of normal and endometrial tumor samples, we used bisulfite pyrosequencing to analyze the methylation status of 12 CpG sites within the 5 0 untranslated region of exon 1 (Figure 1c) . We observed that only 11% of the CpGs have at least 10% methylation in normal samples compared with 33% of the CpGs being methylated in tumors, P ¼ 0.012. Our methylation-specific PCR and pyrosequencing data both showed increased methylation that correlated with survivin overexpression; this suggested that DNA methylation of the survivin promoter might inhibit the binding of a transcriptional repressor. The tumor suppressor protein, p53, is a welldocumented repressor of survivin (Hoffman et al., 2002; Mirza et al., 2002; Esteve et al., 2005) and the p53-binding site in the survivin promoter contains three internal CpG sites. Pyrosequencing data showed that none of the normal samples are methylated at the p53-binding site, whereas 64% of the tumors are methylated at this site ( Figure 1c) . We hypothesized that DNA methylation could inhibit p53 binding thereby relieving survivin of p53-mediated transcriptional repression.
Several approaches have been used to show survivin repression by p53, including UV irradiation (Hoffman et al., 2002) , doxorubicin treatment (Hoffman et al., 2002; Esteve et al., 2005) and p53 overexpression (Mirza et al., 2002) . To validate that p53 represses survivin expression in endometrial cells, we treated the Ishikawa endometrial cancer cell line with the p53-inducing drug, doxorubicin. Immunoblot analysis showed a dosedependent increase in the nuclear accumulation of p53 that correlated with decreased survivin levels ( Figure 2a) . Similarly, survivin was repressed after doxorubicin treatment in wild-type (wt) HCT116 colon cancer cells, but not in p53-null cells, which is consistent with the finding that repression of survivin by doxorubicin treatment is mediated through p53 (Esteve et al., 2005) (Figure 2b ). E2F1 has been reported to be induced by doxorubicin (Meng et al., 1999) and serves as a control for drug induction in both wt and p53-null cells.
Methylation-specific PCR analysis indicated that the survivin promoter in both the HCT116 wt and p53-null cell lines was methylated. To determine whether survivin promoter methylation regulates gene expression, both cell lines were treated with the hypomethylation agent, 5-aza-2-deoxy-cytidine (decitabine), for 4 days to demethylate the survivin promoter (Figure 3a) . Immunoblot and quantitative reverse transcriptase PCR analysis showed that survivin was repressed after decitabine treatment in the wt cells, but not in the p53-null cells (Figures 3b and c) . We concluded that survivin was repressed by demethylation and that this repression is dependent on p53. The c-Myc gene is another oncogene, which has also been shown by others to be repressed by decitabine treatment. We found that in both wt and p53-null HCT116 cells, c-Myc was repressed equally after decitabine treatment. This indicates that decitabine-mediated c-Myc repression is independent of p53 regulation.
We have shown that demethylation of the survivin promoter results in survivin repression through a p53-dependent mechanism (Figure 3) . We wanted to determine whether the methylation state of the survivin promoter could affect the DNA binding of p53. Methylated and unmethylated double-stranded oligonucleotide probes containing the p53-binding-site sequence from the survivin promoter were end-labeled for gel-shift analysis. We observed a strong gel shift in the presence of purified human p53 protein with the unmethylated probe, but a greatly diminished shift with the methylated probe (Figure 4a ), indicating that p53 binding to the survivin promoter was reduced by DNA methylation. Preincubation with an anti-p53 antibody resulted in complete elimination of the gel-shift signal, indicating a specific interaction between the probe and p53. The transcription factor, E2F1, is an activator of survivin and its binding site overlaps the p53-binding site in the survivin promoter. To determine whether methylation specifically inhibits p53 binding or whether E2F1 binding would be similarly affected, we incubated nuclear lysates, enriched with E2F1 protein, with the methylated and unmethylated probes. We observed that E2F1 binding resulted in an equal gel shift for both the probes and was therefore not affected by methylation (Figure 4b ). Preincubation with an anti-E2F1 antibody resulted in a diminished gel-shift signal, and the presence of a supershift indicated a specific interaction between the probe and E2F1. We concluded that DNA methylation could specifically inhibit the binding of p53 to the survivin promoter.
To determine whether de-repression of gene expression by DNA methylation was specific to survivin or whether this was a more universal mechanism of p53-mediated repression, we treated HCT116 wt and p53-null cells with decitabine or vehicle, and then analyzed the gene expression by microarray. We identified 50 genes, which exhibited a statistically significant repression after decitabine treatment in the wt cells, but a non-significant (or less significant) change in the p53-null cells. Subsequent analysis indicated that 46 out of the 50 identified genes (92%) contained CpG islands in their promoters and/or within their first two exons. These 46 genes are listed in Supplementary Table 1 . Notably, the majority of these genes are associated with cancer progression and/or cell proliferation. We selected a subset of genes: HMGB1, UNC84b, Nek2, CDC25C and CCNF for validation. Quantitative reverse transcriptase PCR analysis indicated that HMGB1, Nek2 and CDC25C exhibited statistically significant, p53-dependent gene repression by decitabine treatment (HMGB1 mean wt repression ¼ 65%, mean p53-null repression ¼ 30%, P ¼ 0.042; Nek2 wt ¼ 68%, p53-null ¼ 10%, P ¼ 0.028; CDC25C wt ¼ 89%, p53-null ¼ 59%, P ¼ 0.0099). We concluded that gene de-repression by methylation may be a common mechanism of gene regulation that has been previously unrecognized. Further studies will be necessary to determine which of the identified genes are truly repressed by demethylation in a p53-dependent manner. There were also several genes that were repressed by decitabine treatment in a p53-independent manner, suggesting that other transcriptional repressors may be similarly regulated. Earlier studies showed that methylation of the hTERT promoter at the CTCF-binding site inhibited the binding of CTCF, thus, de-repressing hTert in human tumors (Renaud et al., 2005 (Renaud et al., , 2007 . Similarly, binding of various E2F transcription factors was shown to be inhibited by DNA methylation in a promoterspecific context (Campanero et al., 2000) .
These results suggest that oncogene de-repression is an underappreciated result of epigenetic regulation by DNA methylation. Demethylation induced by decitabine is traditionally thought to be active in tumors by allowing for the re-expression of tumor suppressor genes. However, our results indicate an additional important mechanism to decrease the expression of oncogenes, such as survivin, through the p53-dependent repression. As gene regulation by DNA methylation is highly tissue/context-specific, it will be important to determine how survivin gene expression is affected by decitabine treatment in tumors of other tissue types.
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